[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @CheckOrphan Rare Diseases Rare Diseases posts on X about dyne therapeutics, people with, japan, $abbv the most. They currently have XXXXXX followers and XXX posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::29982331/interactions)  - X Week XXX -XX% - X Month XXXXX +70% - X Months XXXXXX +172% - X Year XXXXXX +59% ### Mentions: XX [#](/creator/twitter::29982331/posts_active)  - X Week XX -XX% - X Month XX +9.70% - X Months XXX +144% - X Year XXX +26% ### Followers: XXXXXX [#](/creator/twitter::29982331/followers)  - X Week XXXXXX +0.02% - X Month XXXXXX +0.08% - X Months XXXXXX -XXXX% - X Year XXXXXX -XXXX% ### CreatorRank: undefined [#](/creator/twitter::29982331/influencer_rank)  ### Social Influence [#](/creator/twitter::29982331/influence) --- **Social category influence** [stocks](/list/stocks) [countries](/list/countries) **Social topic influence** [dyne therapeutics](/topic/dyne-therapeutics), [people with](/topic/people-with), [japan](/topic/japan), [$abbv](/topic/$abbv), [iga](/topic/iga), [$4528t](/topic/$4528t) **Top assets mentioned** [Dyne Therapeutics, Inc. Common Stock (DYN)](/topic/dyne-therapeutics) [AbbVie Inc (ABBV)](/topic/$abbv) ### Top Social Posts [#](/creator/twitter::29982331/posts) --- Top posts by engagements in the last XX hours "Novo Nordisk Submits Biologics License Application (BLA) to FDA for Mim8; An Investigational Prophylaxis Treatment for People with Hemophilia A with or without Inhibitors - For More Information Visit @novonordisk #Hemophilia #Rare_diseases" [X Link](https://x.com/CheckOrphan/status/1972668872164606161) [@CheckOrphan](/creator/x/CheckOrphan) 2025-09-29T14:24Z 18.1K followers, XXX engagements "Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy - For More Information Visit @Dyne_tx #Duchenne #Muscular_Dystrophy #Rare_Diseases" [X Link](https://x.com/CheckOrphan/status/1972700098527117316) [@CheckOrphan](/creator/x/CheckOrphan) 2025-09-29T16:28Z 18.1K followers, XXX engagements "AbbVie Submits Biologics License Application to FDA for Pivekimab Sunirine (PVEK) in Rare Blood Cancer BPDCN - For More Information Visit @abbvie #Rare_diseases #Blood_Cancer #BPDCN" [X Link](https://x.com/CheckOrphan/status/1973392385963876394) [@CheckOrphan](/creator/x/CheckOrphan) 2025-10-01T14:19Z 18.1K followers, XXX engagements "Dyne Therapeutics Reports One-Year Data Showing Meaningful Functional Gains with Z-Basivarsen in Myotonic Dystrophy Type X (DM1) - For More Information Visit @Dyne_tx #DM1 #Rare_Diseases #Myotonic_Dystrophy #OrphanDrugs #Drug_research" [X Link](https://x.com/CheckOrphan/status/1975579659309121583) [@CheckOrphan](/creator/x/CheckOrphan) 2025-10-07T15:11Z 18.1K followers, XXX engagements "argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG - For More Information Visit @argenxglobal #MyastheniaGravis #FDA #Rare_Diseases #OrphanDrugs #Drug_Discovery #VYVGART" [X Link](https://x.com/CheckOrphan/status/1959984592934326657) [@CheckOrphan](/creator/x/CheckOrphan) 2025-08-25T14:21Z 18.1K followers, XXX engagements "Ipsen Wins Japanese Approval for Bylvay to Treat Pruritus in Children with Rare Liver Disorder Progressive Familial Intrahepatic Cholestasis (PFIC) - For More Information Visit #Rare_diseases #PFIC #progressive_Familial_Intrahepatic_Cholestasis" [X Link](https://x.com/CheckOrphan/status/1969035875955699925) [@CheckOrphan](/creator/x/CheckOrphan) 2025-09-19T13:48Z 18.1K followers, XXX engagements "Neurocrine Biosciences: INGREZZA Achieves Robust Symptomatic Remission in Tardive Dyskinesia Patients in KINECT-PRO Phase X Study - For More Information Visit @neurocrine #INGREZZA #Rare_Diseases #OrphanDrugs #Tardive_Dyskinesia #Drug_Research" [X Link](https://x.com/CheckOrphan/status/1970473915983225323) [@CheckOrphan](/creator/x/CheckOrphan) 2025-09-23T13:02Z 18.1K followers, XXX engagements "CSL Vifor and Travere Therapeutics Highlight Inclusion of FILSPARI in Updated 2025 KDIGO Guidelines for IgA Nephropathy Treatment - For More Information Visit @CSL @TravereRare #Rare_Diseases #OrphanDrugs #IgANephropathy #IgAN #Drug_research" [X Link](https://x.com/CheckOrphan/status/1971555201527287894) [@CheckOrphan](/creator/x/CheckOrphan) 2025-09-26T12:39Z 18.1K followers, XXX engagements "Neurocrine Biosciences Reports Three-Year Data Showing Sustained Chorea Improvement and Long-Term Safety of INGREZZA in Huntingtons Disease - For More Information Visit @neurocrine #HuntingtonDisease #Rare_Diseases #OrphanDrugs" [X Link](https://x.com/CheckOrphan/status/1975195704688787610) [@CheckOrphan](/creator/x/CheckOrphan) 2025-10-06T13:45Z 18.1K followers, XXX engagements "Ono Pharmaceutical Reports Positive Interim Phase X Results for ONO-2808 in Multiple System Atrophy (MSA) - For More Information Visit @Ono_pharma_PR #Multiple_System_Atrophy #MSA #Rare_Diseases #OrphanDrugs #Drug_Research #Ono_pharma" [X Link](https://x.com/CheckOrphan/status/1976653704112771086) [@CheckOrphan](/creator/x/CheckOrphan) 2025-10-10T14:19Z 18.1K followers, XXX engagements "FDA Approves Regenerons Libtayo as First Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) - For More Information Visit @Regeneron #CSCC #Rare_Diseases #FDA #Squamous_Cell_Carcinoma #OrphanDrugs #Libtayo" [X Link](https://x.com/CheckOrphan/status/1976257861287043215) [@CheckOrphan](/creator/x/CheckOrphan) 2025-10-09T12:06Z 18.1K followers, XXX engagements "Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome - For More Information Visit @TayshaGTx #Rare_Diseases #OrphanDrugs #FDA #Rett_Syndrome #Drug_research" [X Link](https://x.com/CheckOrphan/status/1973755779154067471) [@CheckOrphan](/creator/x/CheckOrphan) 2025-10-02T14:23Z 18.1K followers, XXX engagements "Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma - For More Information Visit @AkesoInc #HCC #Rare_Diseases #OrphanDrugs #Hepatocellular_Carcinoma" [X Link](https://x.com/CheckOrphan/status/1967594751198462334) [@CheckOrphan](/creator/x/CheckOrphan) 2025-09-15T14:21Z 18.1K followers, XXX engagements "NEJM Publishes Study Showing How Regenerons DB-OTO Restored Hearing in XX of XX Children with Profound Genetic Hearing Loss - For More Information Visit @Regeneron #Hearing_Loss #FDA #NEJM #Rare_Diseases #OrphanDrugs #Pediatrics" [X Link](https://x.com/CheckOrphan/status/1977716751488929953) [@CheckOrphan](/creator/x/CheckOrphan) 2025-10-13T12:43Z 18.1K followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@CheckOrphan Rare Diseases
Rare Diseases posts on X about dyne therapeutics, people with, japan, $abbv the most. They currently have XXXXXX followers and XXX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXX -XX%
- X Month XXXXX +70%
- X Months XXXXXX +172%
- X Year XXXXXX +59%
Mentions: XX #
- X Week XX -XX%
- X Month XX +9.70%
- X Months XXX +144%
- X Year XXX +26%
Followers: XXXXXX #
- X Week XXXXXX +0.02%
- X Month XXXXXX +0.08%
- X Months XXXXXX -XXXX%
- X Year XXXXXX -XXXX%
CreatorRank: undefined #
Social Influence #
Social category influence stocks countries
Social topic influence dyne therapeutics, people with, japan, $abbv, iga, $4528t
Top assets mentioned Dyne Therapeutics, Inc. Common Stock (DYN) AbbVie Inc (ABBV)
Top Social Posts #
Top posts by engagements in the last XX hours
"Novo Nordisk Submits Biologics License Application (BLA) to FDA for Mim8; An Investigational Prophylaxis Treatment for People with Hemophilia A with or without Inhibitors - For More Information Visit @novonordisk #Hemophilia #Rare_diseases"
X Link @CheckOrphan 2025-09-29T14:24Z 18.1K followers, XXX engagements
"Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy - For More Information Visit @Dyne_tx #Duchenne #Muscular_Dystrophy #Rare_Diseases"
X Link @CheckOrphan 2025-09-29T16:28Z 18.1K followers, XXX engagements
"AbbVie Submits Biologics License Application to FDA for Pivekimab Sunirine (PVEK) in Rare Blood Cancer BPDCN - For More Information Visit @abbvie #Rare_diseases #Blood_Cancer #BPDCN"
X Link @CheckOrphan 2025-10-01T14:19Z 18.1K followers, XXX engagements
"Dyne Therapeutics Reports One-Year Data Showing Meaningful Functional Gains with Z-Basivarsen in Myotonic Dystrophy Type X (DM1) - For More Information Visit @Dyne_tx #DM1 #Rare_Diseases #Myotonic_Dystrophy #OrphanDrugs #Drug_research"
X Link @CheckOrphan 2025-10-07T15:11Z 18.1K followers, XXX engagements
"argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG - For More Information Visit @argenxglobal #MyastheniaGravis #FDA #Rare_Diseases #OrphanDrugs #Drug_Discovery #VYVGART"
X Link @CheckOrphan 2025-08-25T14:21Z 18.1K followers, XXX engagements
"Ipsen Wins Japanese Approval for Bylvay to Treat Pruritus in Children with Rare Liver Disorder Progressive Familial Intrahepatic Cholestasis (PFIC) - For More Information Visit #Rare_diseases #PFIC #progressive_Familial_Intrahepatic_Cholestasis"
X Link @CheckOrphan 2025-09-19T13:48Z 18.1K followers, XXX engagements
"Neurocrine Biosciences: INGREZZA Achieves Robust Symptomatic Remission in Tardive Dyskinesia Patients in KINECT-PRO Phase X Study - For More Information Visit @neurocrine #INGREZZA #Rare_Diseases #OrphanDrugs #Tardive_Dyskinesia #Drug_Research"
X Link @CheckOrphan 2025-09-23T13:02Z 18.1K followers, XXX engagements
"CSL Vifor and Travere Therapeutics Highlight Inclusion of FILSPARI in Updated 2025 KDIGO Guidelines for IgA Nephropathy Treatment - For More Information Visit @CSL @TravereRare #Rare_Diseases #OrphanDrugs #IgANephropathy #IgAN #Drug_research"
X Link @CheckOrphan 2025-09-26T12:39Z 18.1K followers, XXX engagements
"Neurocrine Biosciences Reports Three-Year Data Showing Sustained Chorea Improvement and Long-Term Safety of INGREZZA in Huntingtons Disease - For More Information Visit @neurocrine #HuntingtonDisease #Rare_Diseases #OrphanDrugs"
X Link @CheckOrphan 2025-10-06T13:45Z 18.1K followers, XXX engagements
"Ono Pharmaceutical Reports Positive Interim Phase X Results for ONO-2808 in Multiple System Atrophy (MSA) - For More Information Visit @Ono_pharma_PR #Multiple_System_Atrophy #MSA #Rare_Diseases #OrphanDrugs #Drug_Research #Ono_pharma"
X Link @CheckOrphan 2025-10-10T14:19Z 18.1K followers, XXX engagements
"FDA Approves Regenerons Libtayo as First Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) - For More Information Visit @Regeneron #CSCC #Rare_Diseases #FDA #Squamous_Cell_Carcinoma #OrphanDrugs #Libtayo"
X Link @CheckOrphan 2025-10-09T12:06Z 18.1K followers, XXX engagements
"Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome - For More Information Visit @TayshaGTx #Rare_Diseases #OrphanDrugs #FDA #Rett_Syndrome #Drug_research"
X Link @CheckOrphan 2025-10-02T14:23Z 18.1K followers, XXX engagements
"Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma - For More Information Visit @AkesoInc #HCC #Rare_Diseases #OrphanDrugs #Hepatocellular_Carcinoma"
X Link @CheckOrphan 2025-09-15T14:21Z 18.1K followers, XXX engagements
"NEJM Publishes Study Showing How Regenerons DB-OTO Restored Hearing in XX of XX Children with Profound Genetic Hearing Loss - For More Information Visit @Regeneron #Hearing_Loss #FDA #NEJM #Rare_Diseases #OrphanDrugs #Pediatrics"
X Link @CheckOrphan 2025-10-13T12:43Z 18.1K followers, XXX engagements